CRASH2 in Germany [ISRCTN86750102] by Chung, CH et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Trials
Open Access Letter to the Editor
CRASH2 in Germany [ISRCTN86750102]
CH Chung*1, A Freiberger1, M Kalkum2, SP Luntz1, H Shakur3 and CM Seiler4
Address: 1University of Heidelberg, Medical Faculty, Coordination Centre for Clinical Trials (KKS), Germany, 2Kreiskrankenhaus Tirschenreuth, 
Department of Surgery, Germany, 3University of London, London School of Hygiene and Tropical Medicine (LSHTM), UK and 4University of 
Heidelberg, Medical Faculty, Study Centre of the German Surgical Society (SDGC), Germany
Email: CH Chung* - chin-hee.chung@med.uni-heidelberg.de; A Freiberger - anja.freiberger@med.uni-heidelberg.de; 
M Kalkum - mathias.kalkum@krankenhaus-tirschenreuth.de; SP Luntz - steffen.luntz@med.uni-heidelberg.de; 
H Shakur - Haleema.Shakur@lshtm.ac.uk; CM Seiler - christoph_seiler@med.uni-heidelberg.de
* Corresponding author    
In June 2005, the Study Centre of the German Surgical
Society (SDGC) in Heidelberg, Germany [1] agreed to par-
ticipate in the investigator initiated trial CRASH2 [2]. Reg-
ulatory and administrative affairs within Germany were
assigned to the Coordination Centre for Clinical Trials
(KKS) at the University of Heidelberg, Germany.
CRASH2 is a multinational trial sponsored by the London
School of Hygiene and Tropical Medicine (LSHTM), Great
Britain, which aims to determine the effect of the antifibri-
nolytic agent tranexamic acid on death and transfusion
requirement in adult trauma patients with ongoing signif-
icant haemorrhage, or who are considered to be at risk of
significant haemorrhage. In addition, the effect on the risk
of non-fatal vascular events (either haemorrhagic or
occlusive) will be assessed. So far, hospitals in more than
30 countries have been involved and over 1300 patients
have been randomised.
The KKS and the SDGC recruited several collaborating
hospitals and prepared the request for authorisation of
CRASH2 to the competent authority in Germany, the
BfArM (Bundesinstitut für Arzneimittel und Medizin-
produkte) and the independent ethics committees. This
process turned out to be complicated and did not match
the requirements of other EU countries which had already
approved the trial.
The main difference is the way in which German authori-
ties and authorities of some other countries have inter-
preted the EU Directive (Directive 2001/20/EC) with
regards to the need for 'adequate' indemnity for clinical
trials [3]. As European legislation about what constitutes
'adequate' indemnity is not harmonised, somecompetent
authorities as part of their assessment, will judge the ade-
quacy of the insurance provided whereas others insist on
a set limit.
The indemnity insurance for CRASH2 procured by the
LSHTM for all participating hospitals throughout the
world (except for the USA) did not comply with the limits
required by the federal German drug law (AMG).
These set limits have resulted in the need to purchase dif-
ferent and separate limits for the states where prescribed
limits apply and represent a disadvantage to a German
participation.
In Germany, the required limit per person is 500,000 Euro
and the limit per trial is up to 15,000,000 Euro. Some
insurers do not want to expose themselves to this much of
a risk for one trial. This has led to very few insurers willing
to insure clinical trials in Germany and can make insur-
ances for investigator initiated trials too expensive. This in
turn can lead to the unethical situation where non-com-
mercial clinical trials cannot take place.
For more than nine months the KKS and the SDGC have
been trying to procure a separate insurance for CRASH2 in
Germany. Unfortunately, these attempts have not been
successful. The only German insurance that offered an
indemnity insurance did not consider CRASH2 a mere
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pharmacological trial and therefore requested additional
fees in order to insure surgical risks not associated with
the treatment under investigation and finally offered a
premium (cost: over 22,000 Euro) that would only cover
the first 50 patients randomised in CRASH2. The fact that
risks not associated with the trial intervention are assessed
as part of the trial indemnity is not comprehensible to the
KKS and to the SDGC. As a result, LSHTM is now trying to
procure a separate indemnity insurance for Germany in
Great Britain but as the insurance laws differ between the
two countries, the terms and conditions obtained so far
have not complied with article 40 of the AMG.
In dealing with insurers, it is the authors experience that
some companies fear they would be legally held responsi-
ble to pay for all side effects which might occur during a
trial treatment, regardless as to whether a side effect is
caused by the study drug or not. If this is the position of
the insurers, this will have a major impact on all clinical
trials and this view should be open to public debate.
In Germany, several persons and institutions have been
involved in CRASH2 so far. All participants are still eager
to contribute to CRASH2. The participation of German
patients in CRASH2 is very important since the results of
this trial will be relevant to their future care.
In view of this, harmonisation of insurance requirements
across the EU is urgently needed to alleviate these differ-
ences in order to promote the conduction of multina-
tional clinical trials.
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